U.S. Markets closed

NRx Pharmaceuticals, Inc. (NRXP)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
9.90-0.74 (-6.95%)
At close: 4:00PM EDT
9.90 0.00 (0.00%)
After hours: 07:58PM EDT

NRx Pharmaceuticals, Inc.

913 North Market Street
Suite 111
Wilmington, DE 19801
United States
484 254 6134

Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Dr. Jonathan C. JavittCo-Founder, Chairman & CEON/AN/A1957
Prof. Daniel C. JavittCo-Founder & Chairman of Scientific Advisory BoardN/AN/AN/A
Mr. William V. FrickerChief Financial OfficerN/AN/A1965
Mr. Robert BesthofHead of Operations & Chief Commercial OfficerN/AN/AN/A
Ms. Alessandra Daigneault Esq.Gen. Counsel & Sec.N/AN/AN/A
Mr. Jack HirschfieldSr. Director of Corp. Communications & External AffairsN/AN/AN/A
Dr. Philip T. LavinChief MethodologistN/AN/A1947
Dr. Dennis K. McBride Ph.D.Chief Strategy Officer & Sr. ScientistN/AN/AN/A
Mr. Randolph Guggenheimer IIIChief Bus. OfficerN/AN/AN/A
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


NRx Pharmaceuticals, Inc. a clinical-stage, small molecule pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company was incorporated in 2015 and is headquartered in Wilmington, Delaware.

Corporate Governance

NRx Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.